Aktis Oncology CEO to Present at Key September Investor Conferences…

Event summary

Aktis Oncology CEO Matthew Roden to present at Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026.
Roden also scheduled to participate in Oppenheimer 4th Annual Targeted Radiopharmaceutical Therapies in Oncology Summit on September 17, 2026.
Aktis' radioconjugate platform targets Nectin-4 and B7-H3 expressing tumors, including urothelial, breast, prostate, and lung cancers.
Company has a discovery collaboration with Eli Lilly to develop novel radioconjugates outside its proprietary pipeline.

The big picture

Aktis Oncology's participation in high-profile investor conferences underscores the growing interest in targeted radiopharmaceuticals, particularly for solid tumors. The company's proprietary platform and strategic collaborations position it to address unmet needs in oncology, potentially reshaping treatment paradigms for multiple cancer types. The scale of its pipeline and partnerships with industry leaders like Eli Lilly highlight its ambition to become a key player in the radiopharmaceutical space.

What we're watching

Pipeline Progress: How the advancement of AKY-1189 and AKY-2519 will impact Aktis' market positioning in targeted radiopharmaceuticals.
Strategic Partnerships: Whether the collaboration with Eli Lilly will accelerate the development of novel radioconjugates and expand Aktis' pipeline.
Investor Sentiment: The pace at which investor interest and market valuation will respond to Aktis' presentations at these key conferences.